These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 30546360)

  • 61. Daratumumab for the treatment of multiple myeloma.
    Touzeau C; Moreau P
    Expert Opin Biol Ther; 2017 Jul; 17(7):887-893. PubMed ID: 28434255
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Ex Vivo Efficacy of SAR442257 Anti-CD38 Trispecific T-cell Engager in Multiple Myeloma Relapsed After Daratumumab and BCMA-targeted Therapies.
    Keller AL; Reiman LT; Perez de Acha O; Parzych SE; Forsberg PA; Kim PS; Bisht K; Wang H; van de Velde H; Sherbenou DW
    Cancer Res Commun; 2024 Mar; 4(3):757-764. PubMed ID: 38421887
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Preclinical Development of Near-Infrared-Labeled CD38-Targeted Daratumumab for Optical Imaging of CD38 in Multiple Myeloma.
    Cho N; Ko S; Shokeen M
    Mol Imaging Biol; 2021 Apr; 23(2):186-195. PubMed ID: 32964391
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Expanding anti-CD38 immunotherapy for lymphoid malignancies.
    Wang X; Yu X; Li W; Neeli P; Liu M; Li L; Zhang M; Fang X; Young KH; Li Y
    J Exp Clin Cancer Res; 2022 Jun; 41(1):210. PubMed ID: 35765110
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [Research Progress and Application of Daratumumab in Non-Multiple Myeloma--Review].
    Gao F; Li F
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Oct; 31(5):1574-1578. PubMed ID: 37846719
    [TBL] [Abstract][Full Text] [Related]  

  • 66. CD319 (SLAMF7) an alternative marker for detecting plasma cells in the presence of daratumumab or elotuzumab.
    Soh KT; Tario JD; Hahn T; Hillengass J; McCarthy PL; Wallace PK
    Cytometry B Clin Cytom; 2021 Jul; 100(4):497-508. PubMed ID: 33017079
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Editorial: Immunotherapy in Multiple Myeloma.
    Giuliani N; Malavasi F
    Front Immunol; 2019; 10():1945. PubMed ID: 31475006
    [No Abstract]   [Full Text] [Related]  

  • 68. Controversy in the Use of CD38 Antibody for Treatment of Myeloma: Is High CD38 Expression Good or Bad?
    Plesner T; van de Donk N; Richardson PG
    Cells; 2020 Feb; 9(2):. PubMed ID: 32041300
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Double CD38
    Mykytiv V; Alwaheed A; Mohd Hashim NA
    Hematol Oncol Stem Cell Ther; 2019 Mar; 12(1):64-66. PubMed ID: 29079129
    [TBL] [Abstract][Full Text] [Related]  

  • 70. CD38-bispecific antibody pretargeted radioimmunotherapy for multiple myeloma and other B-cell malignancies.
    Green DJ; O'Steen S; Lin Y; Comstock ML; Kenoyer AL; Hamlin DK; Wilbur DS; Fisher DR; Nartea M; Hylarides MD; Gopal AK; Gooley TA; Orozco JJ; Till BG; Orcutt KD; Wittrup KD; Press OW
    Blood; 2018 Feb; 131(6):611-620. PubMed ID: 29158362
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Targeting of CD38 by the Tumor Suppressor miR-26a Serves as a Novel Potential Therapeutic Agent in Multiple Myeloma.
    Hu Y; Liu H; Fang C; Li C; Xhyliu F; Dysert H; Bodo J; Habermehl G; Russell BE; Li W; Chappell M; Jiang X; Ondrejka SL; Hsi ED; Maciejewski JP; Yi Q; Anderson KC; Munshi NC; Ao G; Valent JN; Lin J; Zhao J
    Cancer Res; 2020 May; 80(10):2031-2044. PubMed ID: 32193289
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Preclinical Development of CD38-Targeted [
    Ghai A; Maji D; Cho N; Chanswangphuwana C; Rettig M; Shen D; DiPersio J; Akers W; Dehdashti F; Achilefu S; Vij R; Shokeen M
    J Nucl Med; 2018 Feb; 59(2):216-222. PubMed ID: 29025987
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Molecular Determinants Underlying the Anti-Cancer Efficacy of CD38 Monoclonal Antibodies in Hematological Malignancies.
    Mustafa N; Azaman MI; Ng GGK; Chng WJ
    Biomolecules; 2022 Sep; 12(9):. PubMed ID: 36139103
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Nanobodies effectively modulate the enzymatic activity of CD38 and allow specific imaging of CD38
    Fumey W; Koenigsdorf J; Kunick V; Menzel S; Schütze K; Unger M; Schriewer L; Haag F; Adam G; Oberle A; Binder M; Fliegert R; Guse A; Zhao YJ; Cheung Lee H; Malavasi F; Goldbaum F; van Hegelsom R; Stortelers C; Bannas P; Koch-Nolte F
    Sci Rep; 2017 Oct; 7(1):14289. PubMed ID: 29084989
    [TBL] [Abstract][Full Text] [Related]  

  • 75. The Anti-CD38 Antibody Therapy in Multiple Myeloma.
    Petrucci MT; Vozella F
    Cells; 2019 Dec; 8(12):. PubMed ID: 31842517
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Anti-Multiple Myeloma Activity of Nanobody-Based Anti-CD38 Chimeric Antigen Receptor T Cells.
    An N; Hou YN; Zhang QX; Li T; Zhang QL; Fang C; Chen H; Lee HC; Zhao YJ; Du X
    Mol Pharm; 2018 Oct; 15(10):4577-4588. PubMed ID: 30185037
    [TBL] [Abstract][Full Text] [Related]  

  • 77. A non-internalised CD38-binding radiolabelled single-domain antibody fragment to monitor and treat multiple myeloma.
    Duray E; Lejeune M; Baron F; Beguin Y; Devoogdt N; Krasniqi A; Lauwers Y; Zhao YJ; D'Huyvetter M; Dumoulin M; Caers J
    J Hematol Oncol; 2021 Nov; 14(1):183. PubMed ID: 34727950
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The Mechanism of Action of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma.
    Moreno L; Perez C; Zabaleta A; Manrique I; Alignani D; Ajona D; Blanco L; Lasa M; Maiso P; Rodriguez I; Garate S; Jelinek T; Segura V; Moreno C; Merino J; Rodriguez-Otero P; Panizo C; Prosper F; San-Miguel JF; Paiva B
    Clin Cancer Res; 2019 May; 25(10):3176-3187. PubMed ID: 30692097
    [TBL] [Abstract][Full Text] [Related]  

  • 79. BCMA-Specific ADC MEDI2228 and Daratumumab Induce Synergistic Myeloma Cytotoxicity via IFN-Driven Immune Responses and Enhanced CD38 Expression.
    Xing L; Wang S; Liu J; Yu T; Chen H; Wen K; Li Y; Lin L; Hsieh PA; Cho SF; An G; Qiu L; Kinneer K; Munshi N; Anderson KC; Tai YT
    Clin Cancer Res; 2021 Oct; 27(19):5376-5388. PubMed ID: 34301753
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Investigational agents in immunotherapy: a new horizon for the treatment of multiple myeloma.
    Varga C; Laubach JP; Anderson KC; Richardson PG
    Br J Haematol; 2018 May; 181(4):433-446. PubMed ID: 29748955
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.